ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

TYK2

tyrosine kinase 2 · also JTK1 · FERM domain containing

13 programs in company-led studies act on TYK2, from 12 companies: 7 in phase 3, 5 approved with new studies. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (10 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
upadacitinibruleAbbVieinhibitorphase 46424 runningJAK1, JAK2, JAK3ChEMBL
ruxolitinibruleIncyteinhibitorphase 49518 runningJAK1, JAK2, JAK3ChEMBL
deucravacitinibruleBristol-Myers Squibb–phase 46012 running–ChEMBL
tofacitinibrulePfizerinhibitorphase 4943 runningJAK1, JAK2, JAK3ChEMBL
filgotinib maleateruleEisaiinhibitorphase 421 runningJAK1, JAK2, JAK3ChEMBL
D-2570ruleInventisBioinhibitorphase 31311 running–the studies' text
filgotinibruleLakefront Biotherapeutics NVinhibitorphase 3464 runningJAK1, JAK2, JAK3ChEMBL
HS-10374Hansoh Pharmaceutical Group–phase 364 running–the company's pipeline
TQH3906Sino Biopharmaceuticalinhibitorphase 364 running–the company's pipeline
FXS5626Fosun Pharma–phase 333 runningJAK1the company's pipeline
brepocitinibrulePfizerinhibitorphase 3252 runningJAK1NCIt
delgocitinibruleLEO Pharmainhibitorphase 3212 runningJAK1, JAK2, JAK3ChEMBL
TYK2 InhibitorruleUsynova Pharmaceuticalsinhibitorno phase11 running–NCIt

Also acted on by the same programs

Conditions their studies are in

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.